Clinical genetic testing for familial melanoma in Italy: A cooperative study

Journal of the American Academy of Dermatology

Volumn 61, Issue 5, 2009, Pages 775-782

  Bruno, William ^a   Ghiorzo, Paola ^a   Battistuzzi, Linda ^a   Ascierto, Paolo A ^b   Barile, Monica ^c   Gargiulo, Sara ^a   Gensini, Francesca ^d   Gliori, Sara ^a   Guida, Michele ^e   Lombardo, Maurizio ^f   Manoukian, Siranoush ^g   Menin, Chiara ^h   Nasti, Sabina ^a   Origone, Paola ^a   Pasini, Barbara ⁱ   Pastorino, Lorenza ^a   Peissel, Bernard ^g   Pizzichetta, Maria Antonietta ^j   Queirolo, Paola ^k   Rodolfo, Monica ^g   Romanini, Antonella ^l   Scaini, Maria Chiara ^m   Testori, Alessandro ^c   Tibiletti, Maria Grazia ⁿ   Turchetti, Daniela ^o   Leachman, Sancy A ^p   Bianchi Scarrà, Giovanna ^a   more..

^a UNIVERSITY OF GENOA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f OSPEDALE DI CIRCOLO   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l UNIVERSITY OF PISA   (Italy)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ UNIVERSITY OF INSUBRIA   (Italy)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p UNIVERSITY OF UTAH   (United States)

more..

Author keywords

cyclin dependent kinase 4; cyclin dependent kinase inhibitor 2A; familial melanoma; genetic testing

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC COUNSELING; HUMAN; ITALY; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; FAMILY HEALTH; GENE FREQUENCY; GENETIC COUNSELING; GENETIC SCREENING; HUMANS; ITALY; MELANOMA; NEOPLASMS, MULTIPLE PRIMARY; POINT MUTATION; SKIN NEOPLASMS;

EID: 70349792450     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.03.039     Document Type: Article

References (40)

1. de Snoo F.A., and Hayward N.K. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230 (2005) 153-186
2. Gruis N.A., van der Velden P.A., Sandkuijl L.A., Prins D.E., Weaver-Feldhaus J., Kamb A., et al. Homozygotes for CDKN2A (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10 (1995) 351-353
3. Borg A., Johannsson U., Johannson O., Häkansson S., Westerdahl J., Mäsbäck A., et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56 (1996) 2497-2500
4. Ciotti P., Struewing J.P., Mantelli M., Chompret A., Avril M.F., Santi P.L., et al. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 67 (2000) 311-319
5. Goldstein A.M., Liu L., Shennan M.G., Hogg D., Tucker M.A., and Struewing J.P. A common founder for the V126D CDKN2A mutation in seven North American melanoma prone families. Br J Cancer 85 (2001) 527-530
6. Hashemi J., Bendahl P.O., Sandberg T., Platz A., Linder S., Stierner U., et al. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes Cancer 31 (2001) 107-116
7. Yakobson E., Eisenberg S., Isacson R., Halle D., Levy-Lahad E., Catane R., et al. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families. Eur J Hum Genet 11 (2003) 288-296
8. Ghiorzo P., Gargiulo S., Pastorino L., Nasti S., Cusano R., Bruno W., et al. E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Hum Mol Genet 15 (2006) 2682-2689
9. Gensini F., Sestini R., Piazzini M., Vignoli M., Chiarugi A., Brandani P., et al. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy. Melanoma Res 17 (2007) 387-392
10. Goldstein A.M., Chan M., Harland M., Gillanders E.M., Hayward N.K., Avril M.F., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66 (2006) 9818-9828
11. Fargnoli M.C., Chimenti S., Keller G., Soyer H.P., Dal Pozzo V., Höfler H., et al. CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. J Invest Dermatol 111 (1998) 1202-1206
12. Ghiorzo P., Ciotti P., Mantelli M., Heouaine A., Queirolo P., Rainero M.L., et al. Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 83 (1999) 441-448
13. Della Torre G., Pasini B., Frigerio S., Donghi R., Rovini D., Delia D., et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85 (2001) 836-844
14. Mantelli M., Pastorino L., Ghiorzo P., Barile M., Bruno W., Gargiulo S., et al. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. Melanoma Res 14 (2004) 443-448
15. Majore S., De Simone P., Crisi A., Eibenschutz L., Binni F., Antigoni I., et al. CDKN2A/ CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma. Pigment Cell Melanoma Res 21 (2008) 209-211
16. Bianchi-Scarrà G, Genuardi M, Pasini B, Tibiletti MG, Varesco L. Condizioni minime per la consulenza genetica in oncologia: Gruppo SIGU-ONC; 2000. Available from: URL:http://www.sigu.net. Accessed October 8, 2008.
17. Bianchi-Scarrà G, Grammatico P, Genuardi M, Pasini B. Raccomandazioni per consulenza e test genetico nel melanoma ereditario: Gruppo SIGU-ONC; 2004. Available from: URL:http://www.sigu.net. Accessed October 8, 2008.
18. Harland M., Mistry S., Bishop D.T., and Newton Bishop J.A. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10 (2001) 2679-2686
19. Vignoli M., Scaini M.C., Ghiorzo P., Sestini R., Bruno W., Menin C., et al. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations. Melanoma Res 18 (2008) 431-437
20. Pastorino L., Bonelli L., Ghiorzo P., Queirolo P., Battistuzzi L., Balleari E., et al. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment Cell Melanoma Res 21 (2008) 700-709
21. Huber J., and Ramos E.S. The P48T germline mutation and polymorphism in the CDKN2A gene of patients with melanoma. Braz J Med Biol Res 39 (2006) 237-241
22. Széll M., Balogh K., Dobozy A., Kemény L., and Oláh J. First detection of the melanoma-predisposing proline-48-threonine mutation of p16 in Hungarians: was there a common founder either in Italy or in Hungary?. Melanoma Res 17 (2007) 251-254
23. Kefford R.F., Newton Bishop J.A., Bergman W., and Tucker M.A. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma genetics consortium. J Clin Oncol 17 (1999) 3245-3251
24. Kefford R., Bishop J.N., Tucker M., Bressac-de Paillerets B., Bianchi-Scarrá G., Bergman W., et al. Genetic testing for melanoma. Lancet Oncol 3 (2002) 653-654
25. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility; adopted on February 20, 1996. J Clin Oncol 14 (1996) 1730-1736
26. Olopade O.I., Offit K., and Garber J.E. Genetic testing for susceptibility to cancer: task force on cancer genetics education. JAMA 279 (1998) 1612-1613
27. Gerstenblith M.R., Goldstein A.M., Tucker M.A., and Fraser M.C. Genetic testing for melanoma predisposition: current challenges. Cancer Nurs 30 (2007) 452-459
28. Zuo L., Weger J., Yang Q., Goldstein A.M., Tucker M.A., Walker G.J., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12 (1996) 97-99
29. Soufir N., Avril M.F., Chompret A., Demenais F., Bombled J., Spatz A., et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France: the French familial melanoma study group. Hum Mol Genet 7 (1998) 209-216
30. Molven A., Grimstvedt M.B., Steine S.J., Harland M., Avril M.F., Hayward N.K., et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 44 (2005) 10-18
31. Pjanova D., Engele L., Randerson-Moor J.A., Harland M., Bishop D.T., Newton Bishop J.A., et al. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population. Melanoma Res 17 (2007) 185-191
32. Leachman SA, Carucci J, Kohlmann W, Banks K, Asgari M, Bergman W, et al. Evidence-based selection of familial melanoma patients for genetic assessment. J Am Acad Dermatol. In press.
33. Lesueur F., de Lichy M., Barrois M., Durand G., Bombled J., Avril M.F., et al. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer 99 (2008) 364-370
34. Mistry S.H., Taylor C., Randerson-Moor J.A., Harland M., Turner F., Barrett J.H., et al. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 44 (2005) 292-300
35. Crocetti E., Capocaccia R., Casella C., De Lisi V., Ferretti S., Foca F., et al. Associazione Italiana Registri Tumori: I Tumori in Italia Rapporto 2006. Incidenza, mortalità e stime. Epidemiol Prev 30 (2006) 1-147
36. Holland E.A., Schmid H., Kefford R.F., and Mann G.J. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 25 (1999) 339-348
37. Monzon J., Liu L., Brill H., Goldstein A.M., Tucker M.A., From L., et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338 (1998) 879-887
38. Mantelli M., Barile M., Ciotti P., Ghiorzo P., Lantieri F., Pastorino L., et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107 (2002) 214-221
39. Puig S., Malvehy J., Badenas C., Ruiz A., Jimenez D., Cuellar F., et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23 (2005) 3043-3051
40. Ghiorzo P., Pastorino L., Bonelli L., Cusano R., Nicora A., Zupo S., et al. INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol 15 (2004) 70-78